Please assess the completion status of the following clinical trial:

Trial Title: LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients with a lower risk MDS (LOW or INT-1 according to IPSS)~* Red blood cell transfusion dependency of at least 4 Units/8 weeks.~* Not responding to Erythropoietin stimulating agents (ESA) or having a low chance to do so~* Age-adjusted normal cardiac, kidney, liver function~Key Exclusion Criteria:~* Concomitant use of ESA~* Concomitant use of any other investigational drug~* Other malignancy that is not in remission for at least 1 year~* Platelet Count \< 75 x 109/L~* Impaired cardiac function or clinically significant cardiac diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LBH589 (Type: EXPERIMENTAL): During the core phase, all participants received oral LBH589 40 mg (30 mg after a protocol amendment) for 4 months. During the randomization phase, participants with hematological improvement of the erythropoetic system (HI-E) and participants with stable disease, who were randomized to single agent LBH589, continued on single agent LBH589 40mg/30mg for an additional 4 months.
- LBH589 + Epoetin Alfa (Type: EXPERIMENTAL): During the randomized phase, participants randomized to LBH589 + Epoetin Alfa (ESA) received oral LBH589 40mg/30mg + ESA 30000 international units (IU)/week injected subcutaneously for 4 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).